Abcam

BioVision, Inc. is a life science company based in Milpitas, California, specializing in the development, manufacture, and sale of a wide range of research tools and products for the life science research and drug discovery markets globally. The company's offerings include bioassay kits, antibodies, recombinant proteins, enzymes, and various biochemical products designed to facilitate studies in apoptosis, metabolism, cell proliferation, and cellular stress, among other areas. BioVision's products support research into critical health issues such as cancer, diabetes, obesity, and Alzheimer's disease, catering to pharmaceutical and biotechnology companies, academic institutions, hospitals, and government laboratories. Founded in 1996, BioVision operates as a subsidiary of Bioneer A/S and distributes its products through a network of distributors worldwide.

ViaNautis specializes in the development of innovative medications that effectively cross biological barriers, including the blood-brain barrier. The company employs its proprietary PolyNaut technology, a versatile nano-engineered polymer system designed for intracellular delivery. This technology allows for the encapsulation of various therapeutic modalities into polymer nanovesicles, which can selectively target different tissues and cell types. By facilitating the penetration of these barriers, ViaNautis enhances the therapeutic efficacy of the encapsulated molecules, providing significant benefits in medication delivery and treatment outcomes. Collaborating with multiple partners, the company aims to revolutionize how medications are developed and delivered, particularly in addressing challenging medical conditions.

Marker Gene Technologies Inc., based in Eugene, Oregon, develops and manufactures products for the biotechnology and medical industries, having been incorporated in 1993. The company specializes in high-quality research tools for life science researchers, including gene imaging kits and enzyme substrates that support various detection methods. Additionally, Marker Gene Technologies offers contract research services, collaborating with clients on specific projects to advance scientific research and development. As of early 2020, it operates as a subsidiary of Abcam plc.

Expedeon Ltd. specializes in developing and marketing innovative solutions for protein-based research and production, catering to the needs of protein researchers across various applications. Established in 2003 and based in Harston, United Kingdom, the company offers a range of products, including InstantBlue, a ready-to-use protein gel stain, and BradfordUltra, which detects total protein in challenging environments. Its portfolio encompasses polyacrylamide gel electrophoresis equipment, protein protection and refolding kits, purification resins, and enzymes. Expedeon also provides custom services and off-the-shelf products, supporting workflows in life sciences and diagnostics, such as liquid biopsy and immunoassay development. Known for its commitment to quality, all products undergo stringent quality control testing to ensure reliability and ease of use, ultimately saving researchers time and costs. Expedeon operates as a subsidiary of Abcam plc and is fully owned by SYGNIS AG, with laboratory and commercial facilities located in the UK, USA, Singapore, Germany, and Spain, allowing for rapid global delivery of products.

Calico Biolabs, Inc. is a biotechnology company based in Pleasanton, California, that specializes in the manufacture and marketing of recombinant rabbit monoclonal antibodies. Founded in 2011, the company collaborates with diagnostic and pharmaceutical partners to develop custom antibodies aimed at enhancing cancer diagnostics. Calico Biolabs utilizes innovative methods that do not rely on traditional cell fusion and hybridoma techniques, which allows for improved stability, flexibility, and scalability in their antibody production. As of January 2019, Calico Biolabs operates as a subsidiary of Abcam plc.

AxioMx Inc., founded in 2012 and based in Branford, Connecticut, specializes in the discovery, development, production, and delivery of recombinant antibodies. The company provides a comprehensive suite of custom antibody services, catering to the needs of life science researchers across diagnostic, pharmaceutical, biotechnology, and academic sectors. AxioMx's offerings include antigen and project design consultation, recombinant antibody development, antibody optimization, and protein production and purification services. Utilizing proprietary phage display libraries and affinity maturation techniques, the company excels in creating high-affinity, specific antibodies, including those for challenging targets such as phosphorylated proteins and non-immunogenic antigens. Additionally, AxioMx supports various antibody optimization processes, including scFv to IgG conversion and antibody labeling. The company is recognized for its innovative approach to synthetic recombinant antibodies, which serve vital roles in research, diagnostic tests, and therapeutic applications.

Firefly BioWorks, Inc., based in Cambridge, Massachusetts, specializes in developing an open platform that facilitates the creation and utilization of multiplexed biological assays for industrial, academic, and clinical scientists. The company's core technology, Optical Liquid Stamping, enables the rapid and scalable synthesis of encoded, multi-functional particles, allowing for the simultaneous analysis of multiple biomarkers. Firefly BioWorks offers products such as Multiplex Cellular miRNA and Multiplex Circulating miRNA Assays, which utilize their particle technology to analyze up to 68 miRNAs per well. Additionally, the company provides tools like the Firefly Discovery Engine, a web-based resource for literature analysis, and the Firefly Analysis Workbench, which processes raw cytometer data into publication-ready visualizations. Founded in 2009, Firefly BioWorks aims to deliver reliable and cost-effective solutions for comprehensive monitoring of biological systems.

Epitomics is a biotechnology company based in Burlingame, California, with subsidiaries in Hong Kong and Hangzhou, China. It specializes in developing advanced monoclonal antibody technology for research and diagnostic purposes. Epitomics' proprietary RabMAb® technology enables the production of high-affinity, specific, and bioactive antibodies suitable for both in vitro and in vivo applications. The company's offerings include humanized rabbit monoclonal antibodies for potential therapeutic use.

Ascent Scientific, a subsidiary of Abcam, specializes in providing high-quality biochemical tools primarily for the pharmaceutical and chemistry-related industries. The company produces a diverse array of receptor ligands, including receptor agonists, antagonists, ion channel modulators, enzyme inhibitors, and signaling tools. Its products are designed to meet the needs of academic researchers and are known for their high purity and exceptional quality.

MitoSciences was a privately held biotech company located in Eugene, Oregon, founded in 2004. The company specialized in the development and distribution of immunoassay platforms and high-performance monoclonal antibodies, with a focus on advancing mitochondrial research. MitoSciences created products that support critical research areas, particularly in cancer, neurodegeneration, and metabolic disorders. Its offerings included antibody cocktails, cell fractionation kits, sandwich ELISA kits, in-cell ELISA, flow cytometry antibodies, and enzyme activity assays, all designed to aid researchers in studying mitochondrial enzymes and related metabolic processes.